India Vaccine Development Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Vaccine Development Market was valued at USD 527.0 million in 2025 and is projected to reach USD 846.25 million by 2032, growing at a CAGR of approximately 7% during 2026–2032.
India Vaccine Development Market Highlights
| Report Metric | Details |
| Report Name | India Vaccine Development Market |
| Market Size 2025 | USD 527.0 million |
| Market Size 2032 | USD 846.25 million |
| Absolute Growth 2025–2032 | USD 319.25 million |
| CAGR 2026–2032 | 7% |
| Peak Annual Growth | 8.8% in 2029 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Vaccine Type, 2025 | mRNA Vaccines (37% share) |
| Leading Technology Platform, 2025 | Synthetic mRNA (41% share) |
| Leading Disease Targeted, 2025 | COVID-19 (47% share) |
| Leading End User, 2025 | Pharmaceutical Firms (46% share) |
| Fastest-Growing Technology Platform | Adenovirus-Based (9.6% CAGR) |
| Fastest-Growing Disease Targeted | Influenza (8.1% CAGR) |
| Fastest-Growing End User | Biotech Companies (8.6% CAGR) |
| Growing Sector | Pharmaceutical Firms |
| Key End Users | Pharmaceutical Firms, Biotech Companies, Public Health Organizations, Research Institutes |
India Vaccine Development Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Each row of the following table gives one year's estimated growth and the event or demand shift that explains it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 4.3 | The market experienced moderate growth due to ongoing vaccination efforts against diseases like hepatitis B and influenza. |
| 2023 | 6.3 | Increased investments in vaccine research, particularly for mRNA technologies, spurred faster growth compared to the previous year. |
| 2024 | 5.0 | A slowdown occurred as manufacturers adjusted to new regulatory requirements from the Drug Controller General of India. |
| 2025 | 7.4 | boosting overall demand for immunizations. |
| 2026 | 5.9 | The market is expected to see slower growth as competition among pharmaceutical firms intensifies and pricing pressures emerge. |
| 2027 | 5.3 | Investment in vaccine technology is projected to lead to further growth, albeit at a reduced rate due to regulatory challenges. |
| 2028 | 8.4 | Demand is expected to surge again as new vaccines enter the market, particularly for seasonal influenza and other diseases. |
| 2029 | 8.8 | The market is projected to peak with the introduction of advanced vaccine technologies and increased public health initiatives. |
| 2030 | 7.3 | Growth is expected to slow as the market matures and regulatory processes become more stringent, particularly for new vaccine approvals. |
| 2031 | 4.8 | A further slowdown is anticipated as manufacturers face challenges in scaling production efficiently amid rising costs. |
| 2032 | 8.6 | Growth is expected to rebound with renewed focus on vaccine accessibility and new disease targets, particularly through public health campaigns. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Vaccine Development Market Synopsis
Vaccine Development in India involves creating immunizations to prevent infectious diseases, employing various technologies such as live attenuated pathogens and recombinant DNA technology. The main buyer groups include pharmaceutical firms and public health organizations, which drive demand for vaccines. The India Vaccine Development Market is expanding rapidly due to increasing domestic demand and substantial investments in research and development. With over 1.5 billion doses produced in 2021 and a goal to vaccinate 90% of children by 2025, the market is set for notable growth.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Growing domestic demand for vaccines driven by health initiatives | Driver | High | COVID-19 |
| Investment in innovative vaccine technologies to enhance production | Driver | High | mRNA Vaccines |
| Increasing need for vaccines against emerging infectious diseases | Opportunity | High | Influenza |
| Expansion of vaccine distribution networks to remote areas | Opportunity | Medium | Public Health Orgs |
| Regulatory hurdles delaying vaccine approvals | Restraint | High | Viral Vector Vaccines |
| Competition among manufacturers leading to pricing pressures | Restraint | Medium | Pharmaceutical Firms |
| Supply chain disruptions affecting raw material availability | Challenge | High | Biotech Companies |
| Technological challenges in scaling up production | Challenge | Medium | Research Institutes |
Evaluation of Drivers in India Vaccine Development Market (2026–2032)
The table below links each growth driver to the segment it affects and the evidence for it.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increased health initiatives targeting vaccination | COVID-19 | The National Health Mission aims to vaccinate 90% of children by 2025, driving demand for vaccines across the country. |
| Rising investments in mRNA vaccine technology | mRNA Vaccines | India produced over 1.5 billion vaccine doses in 2021, reflecting strong production capabilities and investment in new technologies. |
| Growing focus on pandemic preparedness and response | Influenza | The National Program for Immunization aims to reduce vaccine-preventable diseases, boosting demand for vaccines in the public health sector. |
| Expansion of vaccine exports to global markets | Pharmaceutical Firms | India's vaccine exports reached 66 million doses in 2022, indicating strong international demand for Indian-produced vaccines. |
| Development of new vaccine types to combat emerging diseases | Biotech Companies | The National Biotechnology Development Strategy aims to enhance vaccine innovation and manufacturing capacity, fostering growth in this segment. |
The National Health Mission aims to vaccinate 90% of children by 2025, driving significant demand for vaccines. In 2021, India produced over 1.5 billion vaccine doses, showcasing its strong production capabilities. Vaccine exports reached 66 million doses in 2022, reflecting robust international interest in Indian vaccine products.
Evaluation of Restraints in India Vaccine Development Market
The key brakes on demand, and where they bite hardest, are shown below.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Regulatory hurdles delaying vaccine approvals | Viral Vector Vaccines | The Drug Controller General of India regulates vaccine approvals, which can slow down market entry and affect timelines. |
| Competition among manufacturers leading to pricing pressures | Pharmaceutical Firms | Intense competition has resulted in reduced profit margins for vaccine producers, impacting their financial viability. |
| Supply chain disruptions affecting raw material availability | Biotech Companies | Global supply chain issues have delayed the procurement of essential materials for vaccine production, causing production delays. |
| Technological challenges in scaling up production | Research Institutes | Many facilities struggle to meet the increasing demand for vaccines due to outdated technology, limiting output capabilities. |
| Limited public awareness about new vaccines | Public Health Orgs | Despite efforts, some communities remain unaware of the benefits of newer vaccines, hindering vaccination rates. |
India Vaccine Development Market Challenges
Producers in the India Vaccine Development Market are grappling with rising input costs due to escalating raw material prices, which can elevate production expenses by 15% and squeeze profit margins for over 100 manufacturers. A shortage of skilled professionals hampers progress, as insufficient training limits these manufacturers' ability to meet the high demand for vaccines. Technological limitations restrict innovation, with many firms relying on outdated processes, delaying the introduction of new vaccines and limiting options for clinics. Lengthy approval processes result in significant delays in vaccine availability, affecting public health efforts to vaccinate 90% of children by 2025.
Trends in the India Vaccine Development Market
Below mentioned are some of the trends shaping the India Vaccine Development Market growth.
- Shift Towards mRNA Vaccines: India is increasingly embracing mRNA vaccine technology, especially for emerging diseases like COVID-19. The production of over 1.5 billion doses in 2021 underscores the importance of this trend for future vaccine development.
- Expansion of Vaccine Distribution Networks: The government is improving vaccine distribution networks to effectively reach remote areas. With over 1,000 cold chain points established, access for rural populations is on the rise.
- Increased Focus on Pandemic Preparedness: Since 2021, India has made pandemic preparedness a priority, leading to the creation of the Vaccine Development Fund to support research and development initiatives in the field.
- Emergence of Biotech Companies: Biotech companies are increasingly contributing to vaccine innovation, capturing a growing share of the market and driving the overall expansion of vaccine development efforts.
Investment Opportunities in the India Vaccine Development Market
Some of the investment opportunities in the India Vaccine Development Market are mentioned below.
- Joint Ventures with Local Firms: Pharmaceutical firms are seeking joint ventures to improve production capabilities, particularly in mRNA vaccines, with a projected market size of USD 846.25 million by 2032, creating opportunities for collaboration.
- Investment in Cold Chain Facilities: Public health organizations require improved cold chain facilities for vaccine storage, especially in rural areas, to meet the National Health Mission's targets for vaccination coverage by 2025.
- Expansion into Emerging Markets: With vaccine exports reaching 66 million doses in 2022, there is a significant opportunity to expand into emerging markets, particularly in Southeast Asia, to meet rising global demand.
- Collaboration with Research Institutes: Research institutes are vital for advancing vaccine development, presenting opportunities for partnerships to drive technological advancements and improve vaccine efficacy.
Government Initiatives in the India Vaccine Development Market
The Vaccine Development Fund was established by the Government of India in 2022 to support research and development in vaccine technologies, complementing earlier initiatives like the National Biotechnology Development Strategy from 2021. This fund aims to stimulate innovation and manufacturing capacity, ensuring India's competitiveness in the global vaccine market.
The Indian Council of Medical Research manages funding for vaccine research projects, ensuring that effective solutions are developed and implemented efficiently. The National Health Mission also plays a critical role in approving research initiatives, facilitating collaboration between public health organisations and research institutes, with funding allocated to bolster vaccination efforts nationwide.
Future Insight of the India Vaccine Development Market
The India Vaccine Development Market is set to undergo significant advancements by 2032, primarily driven by improvements in biotechnology and updated regulatory frameworks. The National Biotechnology Development Strategy is expected to increase funding for vaccine research projects, promoting innovation in immunisation solutions. By 2032, the expansion of cold chain infrastructure will improve distribution capabilities, ensuring timely access for healthcare providers. Ongoing collaboration with the Indian Council of Medical Research will likely accelerate research initiatives, ultimately enhancing public health outcomes across the country.
Market Segmentation Analysis
Each segment group is reviewed below, with the leader by share and the fastest grower by CAGR.
By Vaccine Type – mRNA Vaccines Dominated and Is Expected to Record the Fastest Growth
According to Bhawna Singh, Assistant Manager at 6Wresearch, mRNA Vaccines accounted for a 37% market share by vaccine type in 2025. mRNA vaccines represent the largest share in the Indian vaccine development market, largely due to their critical role in combating the COVID-19 pandemic. The production of over 1.5 billion doses in 2021 underscores the widespread reliance on this technology for effective immunisation efforts. Its lead should widen, with a projected CAGR of 9.2% during 2026–2032, the highest in this split. The growth of mRNA vaccines is propelled by ongoing research initiatives and the pressing need for effective responses to infectious diseases. As the National Institute of Immunology continues to explore innovative applications, mRNA's market lead is likely to expand further. Suppliers should prioritise investments in mRNA technology to capture a larger share of the expanding market.
By Technology Platform – Synthetic mRNA Dominated, Adenovirus-Based Expected to Grow Fastest
The largest technology platform category in 2025 was Synthetic mRNA, with a 41% share of total revenue. Synthetic mRNA holds the largest share in the technology platform segment, being vital for the development of mRNA vaccines that have gained significant attention. The established infrastructure in India ensures a dependable supply chain for producing these vaccines. The quickest growth will come from Adenovirus-Based, forecast to expand at a CAGR of 9.6% between 2026 and 2032. Adenovirus-based platforms are rapidly gaining traction due to their effectiveness in creating vaccines for various diseases, including influenza. This growth is supported by increasing collaborations between research institutions and biotech companies. Buyers should consider partnerships with firms specialising in adenovirus-based technologies to enhance their competitive position.
By Disease Targeted – COVID-19 Dominated, Influenza Expected to Grow Fastest
In 2025, COVID-19 led the disease targeted split with a 47% share. COVID-19 vaccines dominate the disease-targeted segment, reflecting the urgent global demand for effective immunisation against the virus. The Indian government's commitment to vaccinating its population has significantly accelerated developments in this area. Influenza is projected to grow fastest, at a CAGR of 8.1% during 2026–2032. Influenza vaccines are witnessing rapid growth as annual outbreaks create a persistent need for timely immunisation. This ongoing demand ensures that the influenza segment will thrive alongside COVID-19 vaccination initiatives. Suppliers must enhance production capabilities for influenza vaccines to seize the increasing market share.
By End User – Pharmaceutical Firms Dominated, Biotech Companies Expected to Grow Fastest
Pharmaceutical Firms held a 46% share of the India Vaccine Development Market by end user in 2025. Pharmaceutical firms lead the end-user segment, serving as the primary producers and distributors of vaccines with extensive resources and established networks. Their significant role in vaccine development is highlighted by India's large-scale production capabilities. Over 2026–2032, Biotech Companies are expected to post the fastest growth, at a CAGR of 8.6%. Biotech companies are experiencing the fastest growth due to their focus on innovative vaccine technologies, which are essential for addressing emerging health threats. Their agility in research and development positions them well to increase their market share. Buyers should engage with biotech firms to access advanced vaccine technologies and solutions.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Vaccine Development Market Outlook
- Market Size of India Vaccine Development Market, 2025
- Forecast of India Vaccine Development Market, 2032
- Historical Data and Forecast of India Vaccine Development Revenues & Volume for the Period 2022 - 2032F
- India Vaccine Development Market Trend Evolution
- India Vaccine Development Market Drivers and Challenges
- India Vaccine Development Price Trends
- India Vaccine Development Porter's Five Forces
- India Vaccine Development Industry Life Cycle
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Vaccine Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By mRNA Vaccines for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Viral Vector Vaccines for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Subunit Vaccines for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By DNA Vaccines for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Technology Platform for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Synthetic mRNA for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Adenovirus-Based for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Protein-Based for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Plasmid-Based for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Disease Targeted for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By COVID-19, Influenza for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Ebola, Zika for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Hepatitis B for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Cancer, HIV for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Pharmaceutical Firms for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Biotech Companies for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Public Health Orgs for the Period 2022 - 2032F
- Historical Data and Forecast of India Vaccine Development Market Revenues & Volume By Research Institutes for the Period 2022 - 2032F
- India Vaccine Development Import Export Trade Statistics
- Market Opportunity Assessment By Vaccine Type
- Market Opportunity Assessment By Technology Platform
- Market Opportunity Assessment By Disease Targeted
- Market Opportunity Assessment By End User
- India Vaccine Development Top Companies Market Share
- India Vaccine Development Competitive Benchmarking By Technical and Operational Parameters
- India Vaccine Development Company Profiles
- India Vaccine Development Key Strategic Recommendations
Market Covered
This report examines the market across the segments below.
By Vaccine Type
- mRNA Vaccines
- Viral Vector Vaccines
- Subunit Vaccines
- DNA Vaccines
By Technology Platform
- Synthetic mRNA
- Adenovirus-Based
- Protein-Based
- Plasmid-Based
By Disease Targeted
- COVID-19
- Influenza
- Ebola
- Zika
- Hepatitis B
- Cancer
- HIV
By End User
- Pharmaceutical Firms
- Biotech Companies
- Public Health Orgs
- Research Institutes
